Equine Mesenchymal Stem Cells: Properties, Sources, Characterization, and Potential Therapeutic Applications.
Authors: Gugjoo Mudasir Bashir, Amarpal, Makhdoomi Dil Mohammad, Sharma Gutulla Taru
Journal: Journal of equine veterinary science
Summary
# Editorial Summary Mesenchymal stem cells (MSCs) derived from adult equine tissues—particularly bone marrow, adipose tissue, and peripheral blood—offer a clinically pragmatic approach to regenerative medicine in horses because they are readily accessible, pose minimal teratogenic risk, and possess inherent immunomodulatory properties that actively suppress inflammatory cascades whilst promoting tissue repair. The review synthesises evidence on MSC characterisation (including surface marker expression and multilineage differentiation capacity) and examines the biological mechanisms underpinning their therapeutic efficacy, demonstrating that these cells can differentiate into osteogenic, chondrogenic, and adipogenic lineages whilst simultaneously modulating local inflammatory microenvironments through paracrine signalling. Beyond their traditional application in musculoskeletal injuries—tendon, ligament, and cartilage damage—emerging evidence supports MSC deployment in diverse conditions including neurological disorders, gastrointestinal pathology, and systemic inflammatory conditions in equines. For practitioners, the practical advantages centre on harvest accessibility without major surgical intervention (particularly for adipose-derived cells), reduced regulatory burden compared to allogeneic products, and mounting clinical evidence of efficacy in conditions previously considered irreversible. However, standardisation of isolation protocols, characterisation methods, and dosing regimens remains inconsistent across studies, necessitating further rigorous clinical trials before MSC therapy can be confidently integrated into evidence-based treatment protocols for all proposed indications.
Read the full abstract on PubMed
Practical Takeaways
- •Adult mesenchymal stem cells offer a practical therapeutic option for equine tissue damage with established safety profile and anti-inflammatory benefits—consider for musculoskeletal injuries and other conditions where conventional therapy has limited effectiveness.
- •MSC therapy is moving beyond traditional use in ligament and tendon work; discuss broader applications with your veterinarian for chronic inflammatory or degenerative conditions.
- •Source and characterization of MSCs matter significantly for therapeutic success—work with veterinarians using properly validated cell products rather than uncharacterized cell preparations.
Key Findings
- •Adult mesenchymal stem cells are preferred for equine therapeutic application due to easy availability, capacity to modulate inflammation, and low teratogenic risk compared to pluripotent stem cells.
- •MSCs demonstrate sustained multiplication, self-renewal capacity, and multilineage differentiation enabling repair of damaged tissues.
- •Mesenchymal stem cells have expanded beyond musculoskeletal applications to diverse clinical problems in horses with results potentially extrapolatable to human medicine.
- •Current limitations in understanding basic biological properties and therapeutic pathways restrict broader clinical application of stem cell therapy in both equine and human medicine.